Jiaqi Yuan

1 month ago | pubs.acs.org | B. Timothy Hummer |Jiaqi Yuan |Yue Huang |Meina Liang

MEDI7219 is a bis-lipidated glucagon-like peptide-1 (GLP-1) analog with enhanced systemic circulation time due to increased reversible binding to albumin. It was being developed as an oral formulation to improve glycemic control and body weight loss in patients with Type 2 diabetes. (1,2) Currently, most GLP-1 receptor agonists are administered via subcutaneous (SC) injection. Thus, oral administration of MEDI7219 may provide a better option for patients by increasing compliance and ease-of-use.

Sep 19, 2024 | dx.doi.org | Jiaqi Yuan |Hui Tan |Yue Huang |Anton I. Rosenbaum

IntroductionClick to copy section linkSection link copied!Over the past decades, antibody-drug conjugates (ADCs) have become an increasingly important therapeutic modality in the biopharmaceutical industry. Currently, there are 13 approved ADCs, and many more under evaluation in clinical trials. (1) ADCs are designed to improve therapeutic index (TI) by targeted payload delivery to increase efficacy and limit the payload off-target toxicity.

Sep 19, 2024 | pubs.acs.org | Jiaqi Yuan |Hui Tan |Yue Huang |Anton I. Rosenbaum

Analytical ChemistryCite this: Anal. Chem. 2024, XXXX, XXXClick to copy citationCitation copied!. This publication is licensed under CC-BY 4.0 . You are free to share (copy and redistribute) this article in any medium or format and to adapt (remix, transform, and build upon) the material for any purpose, even commercially within the parameters below:Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator.